Novel Non-INSTI HIV Treatment Shows Promise in Phase 3 Trial Amid Rising Resistance Concerns
Key Insights
Researchers at Queen Mary University of London have developed the first non-integrase strand-transfer inhibitor (search) (INSTI) single tablet HIV (search) treatment, combining doravirine with islatravir, addressing growing concerns about INSTI resistance in resource-limited settings.
The landmark phase 3 trial published in The Lancet demonstrates that the once-daily doravirine/islatravir combination shows similar efficacy and safety to current integrase inhibitor treatments.
The study recruited higher-than-usual numbers of women, older people, and racially minoritized adults, addressing chronic under-representation in HIV (search) treatment trials.
Researchers at Queen Mary University of London have achieved a significant breakthrough in HIV (search) treatment development, creating the first non-integrase strand-transfer inhibitor (search) (INSTI) single tablet regimen amid mounting concerns about emerging INSTI resistance in resource-limited settings. The landmark phase 3 trial results, published in The Lancet, demonstrate that the once-daily combination of doravirine with islatravir delivers effective and safe treatment for HIV.
Addressing Critical Resistance Concerns
The development comes at a crucial time as public health surveillance data from WHO regions shows evidence of emerging resistance to INSTIs. Currently, all recommended HIV (search) treatment regimens include an INSTI drug that blocks viral integration into the genome. These medications have become the cornerstone of HIV treatment globally due to their high efficacy, high barrier to resistance, favorable tolerability, and low liability for drug-drug interactions.
However, the widespread rollout of INSTI-based treatments across low-income regions has raised concerns about the potential for widespread INSTI resistance, creating an urgent need for alternative non-integrase HIV (search) treatments.
Trial Results and Clinical Significance
The phase 3 trial, led by Professor Chloe Orkin, Director of the SHARE Collaborative at Queen Mary University of London, demonstrated that the doravirine plus islatravir combination achieved similar efficacy and safety profiles compared to existing integrase inhibitors. This represents a critical advancement in providing treatment options for patients who may develop resistance to current standard-of-care regimens.
Professor Orkin emphasized the importance of this development: "This is an important moment in the development of HIV (search) treatments. INSTI-resistance could have huge consequences for the treatment of HIV and the ability of people living with HIV to live long, healthy lives, so novel treatments - like doravirine/islatravir are needed."
Enhanced Trial Diversity
The study distinguished itself by recruiting far higher-than-usual numbers of women, older people, and racially minoritized adults - groups that are chronically under-represented in randomized trials for HIV (search) treatments. This enhanced diversity strengthens the generalizability of the findings across different patient populations.
Future Long-Acting Potential
Beyond its immediate clinical applications, islatravir represents a promising pathway toward more convenient treatment regimens. The drug has long-acting potential and is currently being evaluated as the first weekly tablet to treat HIV (search) at Barts Health NHS Trust and internationally.
Professor Orkin noted the broader implications: "Islatravir is a drug with long-acting potential that is being evaluated as the first ever weekly tablet to treat HIV (search) at Barts Health NHS Trust and internationally, so its safety and efficacy as a daily pill is an important step on the road to more long-acting formulations being developed for HIV."
Clinical Context
People living with HIV (search) can achieve long, healthy lives, but this requires lifelong treatment adherence. The development of alternative treatment mechanisms becomes increasingly important as resistance patterns evolve globally. Professor Orkin previously led the clinical development of the first long-acting injectable HIV treatment, cabotegravir and rilpivirine, demonstrating her continued leadership in advancing HIV treatment options.
The doravirine/islatravir combination offers clinicians and patients a new therapeutic option that maintains efficacy while providing an alternative mechanism of action, potentially serving as a crucial backup strategy in the evolving landscape of HIV (search) treatment resistance.